Affiliation: Massachusetts General Hospital
- Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancerShoko Kure
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer Epidemiol Biomarkers Prev 18:2765-72. 2009..Our data support potential interactions between the VDR, RAS-MAPK and PI3K-AKT pathways, and possible influence by KRAS or PIK3CA mutation on therapy or chemoprevention targeting VDR...
- Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741Kimmie Ng
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 29:1599-606. 2011....
- Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancerKimmie Ng
Division of Medical Oncology, Dana Farber Cancer Institute Boston, MA 02115, USA
J Clin Oncol 26:2984-91. 2008..Higher plasma 25-hydroxyvitamin D(3) (25(OH)D) levels are associated with a decreased incidence of colorectal cancer, but the influence of plasma 25(OH)D on the outcome of patients with established colorectal cancer is unknown...
- Adjuvant and neoadjuvant approaches in gastric cancerKimmie Ng
Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer J 13:168-74. 2007....
- Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803Kimmie Ng
Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
J Natl Cancer Inst 103:1540-51. 2011..Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown...
- Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803Kimmie Ng
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 28:4354-63. 2010..Multivitamin use is widespread in the United States, especially among patients with cancer. However, the influence of multivitamin supplementation on cancer recurrence and death after a curative resection of colon cancer is unknown...
- Reported behavior of eating anything at anytime and risk of colorectal cancer in womenYing Bao
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Int J Cancer 130:1395-400. 2012..05). In conclusion, reports of eating anything at anytime are associated with an increased risk of colorectal cancer in this large prospective cohort study, independent of other potential risk factors for colorectal cancer...
- Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803Shuji Ogino
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02215, USA
Clin Cancer Res 18:890-900. 2012..irinotecan (CPT11), FU and LV (IFL); CALGB 89803]. Cox proportional hazards model was used to assess the prognostic role of BRAF mutation, adjusting for clinical features, adjuvant chemotherapy arm, and MSI status...
- Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancerBrian M Wolpin
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 27:176-85. 2009..Excess energy balance leads to increased circulating insulin and depressed levels of circulating insulin-like growth factor binding protein (IGFBP) -1, which promote cancer cell growth in preclinical models...
- Interaction of molecular markers and physical activity on mortality in patients with colon cancerJeffrey A Meyerhardt
Dana Farber Cancer Institute, Boston, MA 02115, USA
Clin Cancer Res 15:5931-6. 2009..Physical activity in colon cancer survivors has been associated with lower cancer recurrences and improved survival. Whether molecular features of the tumor portend more or less likelihood for benefit from exercise is unknown...
- Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup TrialShuji Ogino
Affiliations of authors Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA SO, XL, YI, MY, NJM, KN, RJM, JAM, CSF Department of Pathology SO, Channing Division of Network Medicine, Department of Medicine DS, CSF, and Department of Surgery MMB, Brigham and Women s Hospital and Harvard Medical School, Boston, MA SO Department of Epidemiology SO, DS and Department of Biostatistics DS, Harvard School of Public Health, Boston, MA Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC DN Memorial Sloan Kettering Cancer Center, New York, NY LBS Hôpital du Sacré Coeur de Montréal, Montreal, Canada RW Loyola University Stritch School of Medicine, Maywood, IL AH current Edward Cancer Center, Naperville, IL AH Northwestern University, Chicago, IL ABB Toledo Community Hospital Oncology Program, Toledo, OH RBM Division of Medical Oncology, Germany
J Natl Cancer Inst 105:1789-98. 2013..Somatic mutations in PIK3CA (phosphatidylinositol-4,5-bisphosphonate 3-kinase [PI3K], catalytic subunit alpha gene) activate the PI3K-AKT signaling pathway and contribute to pathogenesis of various malignancies, including colorectal cancer...
- Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancerBrian M Wolpin
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
Oncologist 18:377-8. 2013..We evaluated tolerability and efficacy of tivozanib (an oral VEGF receptor-1, -2, -3 inhibitor) plus everolimus (an oral mammalian target of rapamycin inhibitor)...
- PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotypeYoshifumi Baba
Department of Medical Oncology, Dana FarberCancer Institute and Harvard Medical School, Boston, Massachusetts, USA
Cancer Epidemiol Biomarkers Prev 19:822-31. 2010..However, the prognostic significance of PTGER2 expression or its relationship with MSI, CIMP, LINE-1 hypomethylation, or PTGS2 (COX-2) remains uncertain...
- Plasma 25-hydroxyvitamin D and risk of pancreatic cancerBrian M Wolpin
Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
Cancer Epidemiol Biomarkers Prev 21:82-91. 2012..Laboratory studies suggest that vitamin D may inhibit pancreatic cancer cell growth. However, epidemiologic studies of vitamin D and pancreatic cancer risk have been conflicting...
- Prediagnostic plasma folate and the risk of death in patients with colorectal cancerBrian M Wolpin
Department of MedicalOncology, Dana Farber Cancer Institute, Boston, MA, USA
J Clin Oncol 26:3222-8. 2008..Therefore, high priority has been given to research investigating the influence of folate on cancer progression in patients with colorectal cancer...
- Dietary insulin load, dietary insulin index, and colorectal cancerYing Bao
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
Cancer Epidemiol Biomarkers Prev 19:3020-6. 2010..On the basis of a novel insulin index for individual foods, we estimated insulin demand for overall diets and assessed its association with colorectal cancer in the Nurses' Health Study and Health Professionals Follow-up Study...
- Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) statusTeppei Morikawa
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215, USA
Cancer Res 73:1600-10. 2013..Furthermore, they suggest that energy balance and metabolism status exerts its effect in a specific carcinogenesis pathway that is less likely dependent on WNT/CTNNB1 activation. Cancer Res; 73(5); 1600-10. ©2012 AACR...
- A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancerJason E Faris
Department of Medical Oncology, Massachusetts General Hospital Cancer Center, POB 221, Boston, MA 02114, USA
Invest New Drugs 30:1614-20. 2012..MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin-β family. We conducted an open-label Phase II study with MKC-1 in patients with advanced pancreatic cancer...
- Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studiesJung Eun Lee
Department of Food and Nutrition, Sookmyung Women s University, Seoul, Korea
Cancer Prev Res (Phila) 4:1808-15. 2011..Current statin use was not associated with risk of overall colorectal cancer. The possibility that statin use may be associated with lower risk of rectal cancer or KRAS wild-type colorectal cancer requires further confirmation...
- Effect of vitamin D supplementation on blood pressure in blacksJohn P Forman
Renal Division and Kidney Clinical Research Institute, Brigham and Women s Hospital, 41 Ave Louis Pasteur, Suite 120, Boston, MA 02115, USA
Hypertension 61:779-85. 2013....
- Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancyNadine J McCleary
Dana Farber Cancer Institute, Department of Medical Oncology, Gastrointestinal Oncology, 450 Brookline Avenue, Boston, MA 02215, USA
Oncologist 18:64-72. 2013..The Cancer-Specific Geriatric Assessment (CSGA) is a primarily self-administered paper survey of validated measures...
- Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimensKimmie Ng
Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Dana 1220, Boston, MA 02215, USA
Clin Cancer Res 19:3987-95. 2013..Everolimus, an oral inhibitor of mTOR, showed efficacy in patients with metastatic colorectal cancers in phase I studies...
- Targeting the epidermal growth factor receptor in metastatic colorectal cancerKimmie Ng
Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA
Crit Rev Oncol Hematol 65:8-20. 2008..Novel strategies of targeting the EGFR pathway to improve efficacy, as well as ongoing research in identifying molecular predictors of response to anti-EGFR agents, will also be reviewed...
- Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation statusMichael S Gordon
Arizona Cancer Center, Tuscon and Scottsdale, AZ, USA
J Clin Oncol 24:4324-32. 2006..Pertuzumab, a humanized antibody that prevents HER2 dimerization and inhibits multiple HER-mediated pathways, was studied in a phase II, multicenter trial in advanced, refractory OC...
- Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapyDavid B Agus
Cedars Sinai Prostate Cancer Center, Los Angeles, CA 90048, USA
J Clin Oncol 25:675-81. 2007..The aim of this single-arm phase II clinical study was to assess the efficacy and safety of single-agent pertuzumab in castration-resistant prostate cancer (CRPC) patients who had experienced progression after prior chemotherapy...
- Detection of proximal adenomatous polyps with screening sigmoidoscopy: a systematic review and meta-analysis of screening colonoscopyJames D Lewis
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 423 Guardian Dr, Seventh Floor Blockley Hall, Philadelphia, PA 19104 6021, USA
Arch Intern Med 163:413-20. 2003..To address this, we performed a systematic review and meta-analysis of screening colonoscopy studies...